ProKidney Corp. filed a Form 8-K on November 9, 2026, disclosing its cash and cash equivalents and marketable securities position as of September 30, 2026, and announcing an updated investor presentation furnished under Regulation FD.

Key Highlights

  • Cash position: ProKidney reported cash and cash equivalents and marketable securities of $141.9 million as of September 30, 2026.
  • Investor presentation updated: The company disclosed that senior management has updated its investor presentation for use in interactions with investors and analysts.
  • Presentation availability: The updated presentation is available on ProKidney's investor relations website and is attached as Exhibit 99.1 to the filing.
  • Regulation FD furnished, not filed: The investor presentation and related Item 7.01 disclosures are furnished, not filed, and will not be incorporated by reference into any registration statement unless specifically identified.
  • Signing officer: The report was signed by James Coulston, Chief Financial Officer, on November 9, 2026.

ProKidney Discloses September 30, 2026 Liquidity and Updated Investor Materials

ProKidney Corp. (NASDAQ:PROK), a Delaware-incorporated company headquartered in Winston-Salem, North Carolina, submitted a current report disclosing two items. Under Item 2.02, the company reported that its combined cash and cash equivalents and marketable securities totaled $141.9 million as of September 30, 2026. This figure was also incorporated by reference into Item 8.01 of the same filing.

Under Item 7.01, the company disclosed an updated investor presentation that senior management "intends to use from time to time when interacting with investors and analysts, among others," according to the filing. The presentation is accessible on the company's investor relations website and is attached as Exhibit 99.1. The company stated that the furnishing of this information "is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete."

ProKidney is identified in the filing as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, and has not elected to use the extended transition period for complying with new or revised financial accounting standards. The Class A common stock, with a par value of $0.0001 per share, is registered on the Nasdaq Stock Market under the symbol PROK.

What Was Disclosed

ProKidney's November 9, 2026 Form 8-K reported $141.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and announced a refreshed investor presentation furnished under Regulation FD, signed by CFO James Coulston.